Skip to main content

Table 3 Survival of patients with t-AML based on age or period of diagnosis

From: Clinicopathological features, risk and survival in lung cancer survivors with therapy-related acute myeloid leukaemia

 

Median OS

P value a

6-month OS

1-year OS

2-year OS

5-year OS

t-AML

1 month

 

25%

13%

6%

3%

Age

 

0.003

    

 < 65 years

4 months

 

41%

22%

6%

2%

 ≥ 65 years

< 1 month

 

11%

5%

5%

4%

Period of diagnosis

 

0.625

    

 1975–1984

2 months

 

14%

14%

0%

0%

 1985–1994

< 1 month

 

25%

0%

0%

0%

 1995–2004

1 month

 

28%

14%

3%

3%

 2005–2015

1 month

 

25%

16%

9%

4%

  1. LC Lung cancer, t-AML Therapy-related acute myeloid leukaemia, OS Overall survival
  2. aThe P value is the median OS of t-AML patients based on age or period of diagnosis